Gilder Gagnon Howe & Co. LLC Has $730,000 Stock Position in Quanterix Co. (NASDAQ:QTRX)

Gilder Gagnon Howe & Co. LLC lessened its stake in Quanterix Co. (NASDAQ:QTRX - Free Report) by 85.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,663 shares of the company's stock after selling 403,617 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned 0.18% of Quanterix worth $730,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in Quanterix by 1.8% in the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock worth $1,150,000 after purchasing an additional 1,963 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Quanterix by 219.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after purchasing an additional 3,915 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Quanterix by 25.8% during the fourth quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock worth $205,000 after buying an additional 3,974 shares during the period. Canada Pension Plan Investment Board raised its position in Quanterix by 64.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after buying an additional 4,000 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Quanterix by 21.9% in the 4th quarter. MetLife Investment Management LLC now owns 23,983 shares of the company's stock valued at $255,000 after acquiring an additional 4,303 shares in the last quarter. Institutional investors own 86.48% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on QTRX. Canaccord Genuity Group lowered their price objective on shares of Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th.

Quanterix Stock Up 5.0 %

NASDAQ:QTRX opened at $5.88 on Monday. Quanterix Co. has a twelve month low of $4.67 and a twelve month high of $19.18. The firm has a market capitalization of $228.08 million, a price-to-earnings ratio of -5.55 and a beta of 1.35. The stock's 50 day moving average price is $6.54 and its two-hundred day moving average price is $9.53.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). The firm had revenue of $35.16 million for the quarter, compared to analyst estimates of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. As a group, analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.